Caribou Biosciences expects cash payments from the workforce reduction and strategic pipeline prioritization to total $2.5 million to $3.5 million. The changes will extend Caribou's cash runway by one ...

Pentixapharm, a clinical-stage biopharmaceutical company, today announced the signing of a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler ...

EQS-News: Eckert & Ziegler SE / Key word (s): Agreement/Incoming Orders Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm 24.04.2025 / 14:00 ...

The funds will be used for pediatric cancer immunology research. "It is going to open up avenues for us to help more children ...

Aurobindo Pharma's Eugia Pharma approved to manufacture Dasatinib Tablets, a bioequivalent to Bristol-Myers Squibb's Sprycel, ...

CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital.

Caribou is enrolling a 20-patient confirmatory cohort using the company's HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). In H2 2025, Caribou ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The pipeline purge comes less than a year after Caribou cut 12% of staff and ended its natural killer (NK) cell therapy ...

In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company ...